Vice president and Global Head of Epidemiology
IQVIA
Boston, United States
Jaclyn L. F. Bosco, PhD, MPH, FISPE is Vice President and Global Head of Epidemiology in Real World Solutions at IQVIA. She is currently the Chair of the ISPE Industry-Service Provider Council, former chair of the ISPE Education Committee, course lead and faculty for the ISPE Biologics including Biosimlars skills course, and an active member of the Biologics SIG. Dr. Bosco is responsible for driving real-world evidence (RWE) generation for regulators, clinicians, patients and payers using passive and primary data collection through clinicians and person-generated health to support the safety and effectiveness of drugs, biologics, and medical devices from early clinical development through the post-approval phase. Her areas of expertise include epidemiologic methods for comparative effectiveness and safety using primary data collection through clinicians and person-generated health, secondary data, or enrinched data; regulatory use of RWE forl label approval or expansion, and RWE for biologics including biosimilars. She sets industry best practices through external thought leadership as an invited speaker at international congresses and conferences on topics such as generating fit-for-purpose solutions using real-world evidence for regulatory decision-making, teaching courses on the evolving regulatory landscape of RWE and biologics/biosimilars as well as authoring peer-reviewed publications and book chapters on subjects such as pragmatic clinical trials and post-authorization safety studies of biologics. She is active with the RWE Alliance on the topics of data quality and access, and is a member of RWE workstreams with Duke-Margolis and the Scientific Committee for the Biologics and Biosimilars Collective Intelligence Consortium. Dr. Bosco received her PhD in Epidemiology and MPH in Epidemiology/Biostatistics from the Boston University School of Public Health where she holds an adjunct appointment and was a research fellow at Dana Farber Cancer Institute/Harvard Medical School.
Disclosure information not submitted.
How to Design a Real-World Study of Biologics Including Biosimilars
Thursday, August 24, 2023
2:00 PM – 6:00 PM ADT
Friday, August 25, 2023
5:15 PM – 6:45 PM ADT
